Please use this identifier to cite or link to this item:
Title: Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
Authors: Providência, Joana 
Rodrigues, Tiago M
Oliveira, Mariana
Bernardes, João
Marques, João Pedro 
Murta, Joaquim N. 
Silva, Rufino 
Issue Date: 2018
Publisher: Hindawi
Serial title, monograph or event: BioMed Research International
Volume: 2018
Abstract: Intravitreal injections of antivascular endothelial growth factors have been considered a milestone in the treatment of neovascular age-related macular degeneration (nAMD). However, the increasing incidence of AMD and the burden of visits and injections overcharge both the patient and the healthcare systems. Real-world solutions depend on treatment protocols aimed at optimizing the number of clinical visits while guaranteeing good functional outcomes. We performed a retrospective analysis of 72 eyes from 63 naïve patients diagnosed with nAMD that underwent a fixed intravitreal protocol consisting of bimonthly injections after a three-month loading dose, with either Aflibercept or Ranibizumab (no predefined criteria for treatment selection). Best corrected visual acuity (BCVA) and optical coherence tomography were analyzed at baseline and during follow-up clinical visits (months 3, 6, 12, and 18). From the included participants, 42 followed a fixed regimen with Aflibercept and 30 with Ranibizumab. At the 12-month visit, there was not a statistically significant difference in the mean change of BCVA between the two groups (p=0.121); however, the mean difference in the central retinal thickness was significantly superior in the Aflibercept group (-142.2 versus -51.5, p=0.011). The described fixed regimen seems to be efficient in the treatment of nAMD in a clinical practice setting.
ISSN: 2314-6133
DOI: 10.1155/2018/9276580
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais
I&D IBILI - Artigos em Revistas Internacionais

Show full item record


checked on Apr 1, 2024


checked on Apr 2, 2024

Page view(s)

checked on Apr 9, 2024


checked on Apr 9, 2024

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons